Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOS3 | P29474 | 4/20 | 0.46 |
| ▸ | NOS2 | P35228 | 4/20 | 0.46 |
| ▸ | NOS1 | P29475 | 2/20 | 0.46 |
| ▸ | PARP1 | P09874 | 2/20 | 0.41 |
| ▸ | DYRK1A | Q13627 | 2/20 | 0.38 |
| ▸ | EPHB4 | P54760 | 1/20 | 0.33 |
| ▸ | DAO | P14920 | 1/20 | 0.32 |
| ▸ | AKT1 | P31749 | 1/20 | 0.32 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.32 |
| ▸ | MTOR | P42345 | 1/20 | 0.32 |
| ▸ | F12 | P00748 | 1/20 | 0.31 |
| ▸ | PLAU | P00749 | 1/20 | 0.31 |
| ▸ | NCF1 | P14598 | 1/20 | 0.31 |
| ▸ | BACE1 | P56817 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | RAB9A | P51151 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30067771 | 1.00 | NOS3 (0.46) | NOS3NOS2NOS1PARP1DYRK1A | |
| SCHEMBL23566378 | 0.89 | NOS3 (0.52) | NOS3NOS2NOS1PARP1 | |
| SCHEMBL20073447 | 0.76 | PARP1 (0.37) | PARP1EPHB4DAOKDM4C | |
| SCHEMBL24210668 | 0.76 | PARP1 (0.38) | NOS3NOS2NOS1PARP1KDM4C | |
| SCHEMBL23566352 | 0.74 | NOS3 (0.41) | NOS3NOS2NOS1PARP1DYRK1A | |
| SCHEMBL25697414 | 0.72 | PARP1 (0.34) | PARP1EPHB4 | |
| SCHEMBL28689843 | 0.72 | PARP1 (0.34) | PARP1EPHB4 | |
| SCHEMBL15770579 | 0.72 | CYP2A6 (0.36) | PARP1EPHB4MAPTKDM4C | |
| SCHEMBL30820792 | 0.69 | PDE4B (0.36) | NOS3NOS2NOS1PARP1 | |
| SCHEMBL23566415 | 0.68 | PARP1 (0.35) | PARP1EPHB4DAO |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3362436-B1 | PROCESS FOR THE CATALYTIC DIRECTED CLEAVAGE OF AMIDE-CONTAINING COMPOUNDS | UNIV ANTWERPEN (BE) | 2021-06-30 | — | — | EP | claimed |
| US-12312339-B2 | Polo like kinase 4 inhibitors | ORIC PHARMACEUTICALS, INC. (US) | 2025-05-27 | — | — | US | disclosed |
| US-20250049780-A1 | THIENOPYRROLE COMPOUNDS | GILEAD SCIENCES, INC. | 2025-02-13 | — | — | US | disclosed |
| US-12070455-B2 | Thienopyrrole compounds | GILEAD SCIENCES, INC. (US) | 2024-08-27 | — | — | US | disclosed |
| US-20240270722-A1 | POLO LIKE KINASE 4 INHIBITORS | ORIC PHARMACEUTICALS, INC. | 2024-08-15 | — | — | US | disclosed |
| EP-4398989-A1 | THIENOPYRROLE COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2024-07-17 | — | — | EP | disclosed |
| CN-117957234-A | Thienopyrrole compounds | 吉利德科学公司 | 2024-04-30 | — | — | CN | disclosed |
| US-20240124426-A1 | POLO LIKE KINASE 4 INHIBITORS | ORIC PHARMACEUTICALS, INC. | 2024-04-18 | — | — | US | disclosed |
| CN-117794529-A | POLO-like kinase 4 inhibitors | 欧瑞克制药公司 | 2024-03-29 | — | — | CN | disclosed |
| US-11858915-B2 | Polo like kinase 4 inhibitors | ORIC PHARMACEUTICALS, INC. (US) | 2024-01-02 | — | — | US | disclosed |
| US-20230365537-A1 | POLO LIKE KINASE 4 INHIBITORS | ORIC PHARMACEUTICALS, INC. | 2023-11-16 | — | — | US | disclosed |
| US-20230270734-A1 | THIENOPYRROLE COMPOUNDS | GILEAD SCIENCES, INC. | 2023-08-31 | — | — | US | disclosed |
| CN-116600811-A | Dihydrofuranopyridine derivatives as RHO-kinase inhibitors | 奇斯药制品公司 | 2023-08-15 | — | — | CN | disclosed |
| CN-116568304-A | Dihydrofuranopyridine derivatives as RHO-kinase inhibitors | 奇斯药制品公司 | 2023-08-08 | — | — | CN | disclosed |
| WO-2023039464-A1 | THIENOPYRROLE COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2023-03-16 | — | — | WO | disclosed |
| EP-3362436-B1 | PROCESS FOR THE CATALYTIC DIRECTED CLEAVAGE OF AMIDE-CONTAINING COMPOUNDS | UNIV ANTWERPEN (BE) | 2021-06-30 | — | — | EP | disclosed |
| EP-3362436-A1 | PROCESS FOR THE CATALYTIC DIRECTED CLEAVAGE OF AMIDE-CONTAINING COMPOUNDS | Universiteit Antwerpen (BE) | 2018-08-22 | — | — | EP | disclosed |
| WO-2017046133-A1 | PROCESS FOR THE CATALYTIC DIRECTED CLEAVAGE OF AMIDE-CONTAINING COMPOUNDS | UNIVERSITEIT ANTWERPEN (BE) | 2017-03-23 | — | — | WO | disclosed |
| US-20040235867-A1 | Tyrosine kinase inhibitors | BILODEAU MARK T (US) | 2004-11-25 | — | — | US | disclosed |
| WO-2003009852-A1 | TYROSINE KINASE INHIBITORS | MERCK & CO., INC. (US) | 2003-02-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230270734-A1 | THIENOPYRROLE COMPOUNDS | SSB, TPMT, LCP2 | NOS3 610/4885NOS2 725/4885NOS1 1218/4885 |
| US-20250049780-A1 | THIENOPYRROLE COMPOUNDS | SSB, TPMT, LCP2 | NOS3 610/4885NOS2 725/4885NOS1 1218/4885 |
| US-20240124426-A1 | POLO LIKE KINASE 4 INHIBITORS | PLK4, PLK2, PLK3 | NOS3 3618/4885NOS2 3963/4885NOS1 3956/4885 |
| US-11858915-B2 | Polo like kinase 4 inhibitors | PLK4, PLK2, PLK3 | NOS3 3618/4885NOS2 3963/4885NOS1 3956/4885 |
| US-12070455-B2 | Thienopyrrole compounds | SSB, TPMT, LCP2 | NOS3 610/4885NOS2 725/4885NOS1 1218/4885 |
| US-20230365537-A1 | POLO LIKE KINASE 4 INHIBITORS | PLK4, PLK2, PLK3 | NOS3 3618/4885NOS2 3963/4885NOS1 3956/4885 |
| US-12312339-B2 | Polo like kinase 4 inhibitors | PLK4, PLK2, PLK3 | NOS3 3618/4885NOS2 3963/4885NOS1 3956/4885 |
| US-20040235867-A1 | Tyrosine kinase inhibitors | ERBB2, TYRO3, TIE1 | NOS3 718/4885NOS2 895/4885NOS1 881/4885 |
| US-20240270722-A1 | POLO LIKE KINASE 4 INHIBITORS | PLK4, PLK2, PLK3 | NOS3 3586/4885NOS2 3886/4885NOS1 3889/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.